Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Rucaparib or physician's choice in metastatic prostate cancer -ORCA

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Recent Advances in the Management of Metastatic Prostate Cancer

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet

Metastatic Prostate Cancer

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Cancers, Free Full-Text

Prostate cancer - The Lancet

Rucaparib Improves rPFS Vs Physician's Choice in BRCA+ mCRPC

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC